Literature DB >> 2891438

erbA-related sequence coding for DNA-binding hormone receptor localized to chromosome 3p21-3p25 and deleted in small cell lung carcinoma.

A Dobrovic1, B Houle, A Belouchi, W E Bradley.   

Abstract

Small-cell lung carcinoma (SCLC) is characterized by a consensus deletion in the short arm of chromosome 3. Using a panel of cell lines and somatic cell hybrids containing various rearrangements involving chromosome 3, we have localized the erbA beta sequence (which codes for a thyroid hormone receptor) to the region 3p21----3p25 which overlaps the consensus deletion in SCLC. Moreover, we have shown by Southern blot analysis that at least one copy of the erbA beta sequence is deleted in all six SCLCs so far studied. Normalized ratios of hybridization intensities of the erbA beta probe to intensities of probes for somatostatin (3q28) and raf(3p24-25) ranged from 0.28 to 0.56 and 0.32 to 0.71, respectively, in the six tumors and tumor lines. In view of the importance of the role these genes are known or suspected to play in biological regulation, our results suggest that the erbA beta sequence is a candidate for a recessive oncogene involved in the genesis of SCLC.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2891438

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  High-resolution physical mapping by combined Alu-hybridization/PCR screening: construction of a yeast artificial chromosome map covering 31 centimorgans in 3p21-p14.

Authors:  H Aburatani; V P Stanton; D E Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

2.  Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.

Authors:  F Rosignolo; V Maggisano; M Sponziello; M Celano; C R T Di Gioia; M D'Agostino; L Giacomelli; A Verrienti; M Dima; V Pecce; C Durante
Journal:  J Endocrinol Invest       Date:  2015-05-24       Impact factor: 4.256

3.  Localization of polymorphic DNA probes frequently deleted in lung carcinoma.

Authors:  D G Albertson; P D Sherrington; P H Rabbitts
Journal:  Hum Genet       Date:  1989-09       Impact factor: 4.132

Review 4.  Genetic features of thyroid hormone receptors.

Authors:  Maha Rebaï; Imen Kallel; Ahmed Rebaï
Journal:  J Genet       Date:  2012       Impact factor: 1.166

5.  Loss of heterozygosity in a gene coding for a thyroid hormone receptor in lung cancers.

Authors:  F Leduc; H Brauch; C Hajj; A Dobrovic; F Kaye; A Gazdar; J W Harbour; O S Pettengill; G D Sorenson; A van den Berg
Journal:  Am J Hum Genet       Date:  1989-02       Impact factor: 11.025

6.  Differential DNA sequence deletions from chromosomes 3, 11, 13, and 17 in squamous-cell carcinoma, large-cell carcinoma, and adenocarcinoma of the human lung.

Authors:  A Weston; J C Willey; R Modali; H Sugimura; E M McDowell; J Resau; B Light; A Haugen; D L Mann; B F Trump
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

7.  Novel pathway for thyroid hormone receptor action through interaction with jun and fos oncogene activities.

Authors:  X K Zhang; K N Wills; M Husmann; T Hermann; M Pfahl
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

Review 8.  Thyroid hormone actions in liver cancer.

Authors:  Sheng-Ming Wu; Wan-Li Cheng; Crystal D Lin; Kwang-Huei Lin
Journal:  Cell Mol Life Sci       Date:  2012-09-06       Impact factor: 9.261

9.  Thyroid hormone regulates stromelysin expression, protease secretion and the morphogenetic potential of normal polarized mammary epithelial cells.

Authors:  M López-Barahona; I Fialka; J M González-Sancho; M Asunción; M González; T Iglesias; J Bernal; H Beug; A Muñoz
Journal:  EMBO J       Date:  1995-03-15       Impact factor: 11.598

Review 10.  Oncogenes and tumor-suppressor genes.

Authors:  T A Lehman; R Reddel; A M Peiifer; E Spillare; M E Kaighn; A Weston; B I Gerwin; C C Harris
Journal:  Environ Health Perspect       Date:  1991-06       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.